GSK to buy Canada's Bellus Health for $2 bln (updated)

BELLUS Health

18/04/2023 07:19

(Adds details of deal)
       April 18 (Reuters) - GSK Plc  GSK.L  will buy
Canada-based late-stage biopharma company Bellus Health Inc
 BLU.TO  in an all-cash deal for $2 billion, the companies said
in a joint statement on Tuesday.
    GSK's offer of $14.75 per share is more than double Bellus's
closing price of $7.26 on the Nasdaq  BLU.O  on Monday.
    The acquisition gives GSK access to camlipixant, which is in
late-stage development for the first-line treatment of adult
patients with refractory chronic cough (RCC).

 (Reporting by Aby Jose Koilparambil in Bengaluru; Editing by
Savio D'Souza)
 ((abyjose.koilparambil@thomsonreuters.com; +917483275231;))